Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Merck and PAREXEL Form Alliance to Develop Biosimilars

By Pharmaceutical Processing | January 12, 2011

Merck and PAREXEL International Corporation, a global biopharmaceutical
services provider, today announced that they have entered into an alliance by
which PAREXEL will provide strategic access to global clinical development
services for designated biosimilar candidates to Merck BioVentures. Merck
BioVentures, a division of Merck, is focused on the delivery of high quality biosimilars
to the patients that need them.

“PAREXEL has extensive, industry-leading experience
with biosimilar development, and we truly understand the scientific
complexities, and regulatory pathways involved,” said Josef von
Rickenbach, chairman and chief executive officer of PAREXEL.”We are
committed to working with Merck BioVentures to assist in advancing its
biosimilar portfolio in this rapidly developing market segment for the benefit of
patients worldwide.” Under the terms of the agreement, PAREXEL will
provide Merck BioVentures with strategic access to a broad range of regulatory strategy
and clinical development planning capabilities for the development of certain
broad classes of biosimilars across various therapeutic areas, including
exclusivity for certain candidates. The agreement also provides for the
establishment of a dedicated Merck BioVentures unit within the PAREXEL
organization. Further details of the agreement were not disclosed.

“Through this agreement, Merck BioVentures has secured
broad strategic access to PAREXEL’s proven biosimilar clinical development experience,”
said Michael Kamarck, president of Merck BioVentures.

“This
agreement positions Merck BioVentures for success with an industry leading
partner that has the expertise and resources to conduct clinical development of
our diverse portfolio of candidates to allow timely delivery of products to the
marketplace.”

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE